Skip to main content
BMRN
NASDAQ Life Sciences

BioMarin Buys Alesta for ALE1, First Oral Hypophosphatasia Therapy

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$67.06
Mkt Cap
$12.9B
52W Low
$49.259
52W High
$70.98
52W Position info
36% above low
Off High info
5.5% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

BMRN sits 36% above its 52-week low of $49.259.

Summary

BioMarin is acquiring Alesta Therapeutics to gain ALE1, a potential first oral therapy for hypophosphatasia. The deal includes a $275 million upfront payment, plus up to $215 million in development and regulatory milestone payments, and a $22 million indemnification escrow. Alesta will spin out all non-ALE1 assets to a new entity, and Alesta employees will transfer to the spinout entity prior to close; no Alesta employees will become BioMarin employees. The transaction is expected to close in Q3 2026 and have a modestly dilutive impact on 2026 financial results. The acquisition adds a clinical-stage program to BioMarin's pipeline, expanding its rare disease portfolio beyond Voxzogo and the Amicus deal, and follows strong Q2 results and raised guidance. The deal is strategically significant for a company with a $12.9B market cap.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — The 8-K discloses up to $215 million in development and regulatory milestone payments, a $22 million indemnification escrow, and a Q3 2026 expected closing.

At the time of this announcement, BMRN was trading at $67.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.9B. The 52-week trading range was $49.26 to $70.98. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

BMRN - Latest Insights

BMRN
Nov 03, 2026, 4:34 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $55.66
Real-time Price: $57.99 info
Change: +$2.33 (+4%) info
Market Cap: $11.232B info
BMRN
Nov 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $54.79
Real-time Price: $57.99 info
Change: +$3.20 (+6%) info
Market Cap: $11.232B info
BMRN
Nov 02, 2026, 4:03 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $57.44
Real-time Price: $57.99 info
Change: +$0.550 (+0.96%) info
Market Cap: $11.232B info
BMRN
Oct 29, 2026, 8:57 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $56.40
Real-time Price: $57.99 info
Change: +$1.59 (+3%) info
Market Cap: $11.232B info
BMRN
Oct 06, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $56.22
Real-time Price: $57.99 info
Change: +$1.77 (+3%) info
Market Cap: $11.232B info